Breadcrumb Home Novartis Corp. Politics & Policy PBM bills drove lobbying spending in 2023 Payment Cigna paying members to use biosimilars draws providers ire Legal Federal healthcare fraud settlements hit decade low in 2020 Legal Novartis pays $678M to resolve suit over sham doctor outings Technology At $2M, priciest ever medicine treats fatal genetic disease Patients Novartis donates data in effort to jump-start antibiotic development Sponsored Content Provided By Amgen and Novartis The Burden of Migraine Government U.S. clears first 'living drug' for childhood leukemia Technology Novartis wins OK for biosimilar version of Amgen's Enbrel Government FDA decision could impact competition for Amgen Load More Sponsored Content
